Skip to content

Evaluation of Shal as an Alternative to Ashoka in Women with Excessive Menstrual Bleeding.

Evaluation of Sal (Shorea robusta C. F. Gaertn.) as an alternative to Ashoka (Saraca asoca (Roxb.) Willd.) in the management of Asrigdar w.s.r. to menorrhagia- A double arm open labeled clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112884
Enrollment
30
Registered
2026-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

None listed

Sponsors

Institution of Teaching and Research in AyurvedaITRA Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women between age group 18 to 45 years both married & unmarried. Abnormal uterine bleeding associated with ovulatory dysfunction (AUB-O).Abnormal uterine bleeding associated with iatrogenic causes (AUB-I specifically IUD related).Patients presenting with at least one of the following features will be included in the study:Excessive bleeding,Prolonged duration.

Exclusion criteria

Exclusion criteria: Structural Pelvic Pathology (PALM): Bleeding due to Cervical Erosion, Carcinoma, Uterine Fibroids (Leiomyoma), or Endometrial Polyps.Systemic & Related Factors: Bleeding following abortion or pregnancy-related complications.Blood Coagulation disorders (AUB-C) or systemic bleeding diathesis. Extragenital bleeding (Bleeding from any site other than the uterus). Suffering from malignancies and chronic systemic diseases like, uncontrolled hypertension (Systolic blood pressure above 160 & Diastolic blood pressure above 100mmhg),uncontrolled diabetes (above the range of 160-200 mg/dl (RBS), Venereal disease. Post-menopausal bleeding.Hb less than 7gm.

Design outcomes

Primary

MeasureTime frame
Changes from baseline to end of treatment in PBAS score.Timepoint: 90th day

Secondary

MeasureTime frame
Changes from baseline to end of treatment in Quality of life by Menorrhagia Multi-Attribute Scale(MMAS)Changes from baseline to end of treatment in mean Hb gm.Timepoint: 90th day

Countries

India

Contacts

Public ContactProf Shilpa donga

Institution of Teaching and Research in Ayurveda(ITRA), Jamnagar

brpayu@gmail.com9427574590

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026